Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
ADIL	ADIAL PHARMACEUTICALS INC	United States	$7.01M	4,054,861	5.41%	94.59%	Net Buying
ACLX	ARCELLX INC	United States	$2.71B	52,796,618	44.19%	55.81%	Net Selling	Net Selling
ACRV	ACRIVON THERAPEUTICS INC	United States	$191.73M	22,636,951	46.35%	53.65%	Net Buying	Net Buying
AEZS	AETERNA ZENTARIS INC	Canada	$9.52M	4,855,876	0.73%	0.00%
ANTX	AN2 THERAPEUTICS INC	United States	$67.88M	29,770,375	54.22%	45.78%	Net Buying
AVTE	AEROVATE THERAPEUTICS INC	United States	$601.00M	27,862,961	66.43%	33.57%	Net Selling	Net Selling
ENTA	ENANTA PHARMACEUTICALS INC	United States	$264.03M	21,155,983	58.46%	41.54%	Net Selling	Net Selling
CTXR	CITIUS PHARMACEUTICALS INC	United States	$116.62M	159,094,781	16.86%	7.74%
DAWN	DAY ONE BIOPHARMACEUTICALS INC	United States	$1.15B	87,384,856	54.70%	45.30%	Net Buying	Net Selling
CYTO	ALTAMIRA THERAPEUTICS LTD	Bermuda	$2.36M	1,477,785	0.52%	0.00%
GLUE	MONTE ROSA THERAPEUTICS INC	United States	$273.34M	50,154,073	24.82%	75.18%
GRTS	GRITSTONE BIO INC	United States	$74.92M	98,065,594	42.92%	22.23%	Net Buying
IGC	IGC PHARMA INC	United States	$27.41M	63,734,439	3.87%	20.14%
IONS	IONIS PHARMACEUTICALS INC	United States	$6.10B	145,751,797	96.31%	3.69%	Net Selling	Net Selling
NKTR	NEKTAR THERAPEUTICS	United States	$242.38M	183,617,817	64.89%	14.15%	Net Selling	Net Selling
JSPR	JASPER THERAPEUTICS INC	United States	$319.05M	15,063,896	60.15%	39.85%	Net Buying	Net Buying
LIPO	LIPELLA PHARMACEUTICALS INC	United States	$4.43M	6,250,034	5.92%	28.26%	Net Buying	Net Buying
TENX	TENAX THERAPEUTICS INC	United States	$7.05M	1,958,245	7.69%	92.31%
TCON	TRACON PHARMACEUTICALS INC	United States	$4.07M	2,275,225	6.34%	93.66%	Net Selling
SONN	SONNET BIOTHERAPEUTICS HOLDINGS INC	United States	$5.40M	3,069,516	1.86%	98.14%	Net Buying
UBX	UNITY BIOTECHNOLOGY INC	United States	$24.84M	16,786,647	25.70%	51.52%	Net Selling	Net Selling
OBIO	ORCHESTRA BIOMED HOLDINGS INC	United States	$158.85M	35,777,412	37.09%	51.45%	Net Buying
VBIV	VBI VACCINES INC	United States	$17.03M	28,432,275	3.92%	96.08%	Net Buying
VALN	VALNEVA SE		$524.39M	138,912,142	0.28%	0.00%
VKTX	VIKING THERAPEUTICS INC	United States	$7.59B	110,268,210	69.23%	9.05%	Net Selling	Net Selling
TRDA	ENTRADA THERAPEUTICS INC	United States	$415.31M	33,601,103	50.54%	49.46%	Net Selling	Net Buying
TCBP	TC BIOPHARM (HOLDINGS) PLC	United Kingdom	$5.02M	63,902,641	0.12%	11.35%
ABUS	ARBUTUS BIOPHARMA CORP	Canada	$488.22M	179,492,199	24.75%	75.25%	Net Selling	Net Selling
NUVL	NUVALENT INC	United States	$4.23B	64,067,638	70.71%	29.29%	Net Selling	Net Selling
PYXS	PYXIS ONCOLOGY INC	United States	$249.97M	58,133,375	15.13%	36.17%	Net Selling
IKT	INHIBIKASE THERAPEUTICS INC	United States	$12.31M	6,476,844	3.63%	84.17%
GANX	GAIN THERAPEUTICS INC	United States	$49.79M	16,219,709	9.53%	2.11%	Net Buying	Net Buying
MRSN	MERSANA THERAPEUTICS INC	United States	$345.71M	121,303,007	42.94%	57.06%	Net Selling
XNCR	XENCOR INC	United States	$1.18B	61,120,272	66.74%	33.26%	Net Buying	Net Selling
ASND	ASCENDIS PHARMA A	Denmark	$7.90B	57,707,439	100.00%	0.00%
LGVN	LONGEVERON INC	United States	$4.20M	2,513,460	14.25%	85.75%	Net Buying	Net Buying
SEEL	SEELOS THERAPEUTICS INC	United States	$3.91M	13,680,576	3.20%	96.80%	Net Buying	Net Buying
MOR	MORPHOSYS AG	Germany	$2.73B	37,655,137	63.38%	0.00%
FENC	FENNEC PHARMACEUTICALS INC	United States	$248.24M	27,099,908	4.18%	95.82%	Net Selling	Net Selling
SGMO	SANGAMO THERAPEUTICS INC	United States	$89.99M	178,906,350	48.59%	17.99%	Net Selling	Net Selling
GERN	GERON CORP	United States	$1.94B	546,059,309	72.04%	1.23%	Net Buying
FNCH	FINCH THERAPEUTICS GROUP INC	United States	$3.60M	1,605,763	1.07%	98.93%	Net Selling	Net Selling
TNXP	TONIX PHARMACEUTICALS HOLDING CORP	United States	$13.52M	84,490,862	17.09%	18.38%
EYEN	EYENOVIA INC	United States	$33.69M	47,386,349	24.06%	27.52%	Net Buying	Net Buying
PYPD	POLYPID LTD	Israel	$7.95M	1,653,559	1.27%	0.00%
BTAI	BIOXCEL THERAPEUTICS INC	United States	$79.81M	30,576,671	4.33%	95.67%	Net Selling	Net Selling
PEPG	PEPGEN INC	United States	$378.55M	32,354,495	50.08%	18.34%	Net Buying	Net Buying
GLSI	GREENWICH LIFESCIENCES INC	United States	$158.92M	12,878,409	4.02%	95.98%	Net Buying	Net Buying
ENLV	ENLIVEX THERAPEUTICS LTD	Israel	$26.97M	18,598,555	1.01%	77.27%
ONCY	ONCOLYTICS BIOTECH INC	Canada	$80.38M	74,423,960	6.91%	0.00%
GTBP	GT BIOPHARMA INC	United States	$5.18M	1,380,633	73.85%	26.15%	Net Buying
KPTI	KARYOPHARM THERAPEUTICS INC	United States	$121.97M	115,067,083	63.84%	32.73%	Net Selling	Net Selling
VIRI	VIRIOS THERAPEUTICS INC	United States	$8.78M	19,257,937	4.47%	5.34%	Net Buying
NERV	MINERVA NEUROSCIENCES INC	United States	$16.99M	6,993,406	6.78%	93.22%	Net Selling
SLDB	SOLID BIOSCIENCES INC	United States	$322.44M	37,756,877	21.64%	78.36%	Net Buying	Net Selling
APGE	APOGEE THERAPEUTICS INC	United States	$2.32B	50,655,671	82.46%	11.78%	Net Buying
TNYA	TENAYA THERAPEUTICS INC	United States	$331.34M	78,516,142	55.16%	44.84%	Net Buying	Net Buying
VIRX	VIRACTA THERAPEUTICS INC	United States	$33.26M	39,272,434	3.63%	96.37%	Net Buying	Net Selling
MLYS	MINERALYS THERAPEUTICS INC	United States	$547.93M	49,631,159	56.06%	43.94%	Net Buying	Net Buying
GNPX	GENPREX INC	United States	$4.05M	1,910,441	48.09%	51.91%	Net Selling	Net Selling
RPHM	RENEO PHARMACEUTICALS INC	United States	$55.14M	33,420,808	61.78%	38.22%	Net Buying
SCPX	SCORPIUS HOLDINGS INC	United States	$4.25M	26,081,890	6.51%	23.91%
FWBI	FIRST WAVE BIOPHARMA INC	United States	$5.53M	2,025,199	0.08%	99.92%	Net Selling	Net Selling
VTYX	VENTYX BIOSCIENCES INC	United States	$240.56M	59,252,349	39.06%	60.94%	Net Selling	Net Selling
TLSA	TIZIANA LIFE SCIENCES LTD	United Kingdom	$86.01M	102,272,614	0.78%	0.00%
MGTX	MEIRAGTX HOLDINGS PLC	United States	$302.46M	64,217,166	51.67%	48.33%	Net Buying
ALLK	ALLAKOS INC	United States	$88.75M	87,873,995	46.03%	53.97%	Net Selling	Net Selling
ENVB	ENVERIC BIOSCIENCES INC	United States	$6.56M	7,294,005	6.71%	5.99%	Net Buying
THAR	THARIMMUNE INC	United States	$4.24M	11,739,676	1.16%	37.18%	Net Buying
AZTR	AZITRA INC	United States	$6.34M	28,804,643	0.16%	55.13%	Net Buying	Net Buying
CYCC	CYCLACEL PHARMACEUTICALS INC	United States	$2.11M	1,318,257	1.23%	98.77%	Net Buying
RVNC	REVANCE THERAPEUTICS INC	United States	$290.22M	88,214,054	73.75%	26.25%	Net Selling	Net Selling
SLN	SILENCE THERAPEUTICS PLC	United Kingdom	$855.63M	118,846,966	17.28%	0.00%
CAPR	CAPRICOR THERAPEUTICS INC	United States	$161.71M	31,399,667	11.23%	88.77%	Net Buying	Net Buying
XFOR	X4 PHARMACEUTICALS INC	United States	$189.77M	167,937,781	57.63%	1.30%	Net Selling	Net Selling
CMMB	CHEMOMAB THERAPEUTICS LTD	Israel	$9.36M	284,094,700	0.99%	5.96%
XTLB	XTL BIOPHARMACEUTICALS LTD	United States	$13.08M	544,906,149	0.04%	20.78%
PHVS	PHARVARIS NV	Netherlands	$1.19B	52,290,212	77.92%	0.00%
APLT	APPLIED THERAPEUTICS INC	United States	$447.90M	105,886,831	57.95%	8.47%	Net Selling	Net Selling
MBRX	MOLECULIN BIOTECH INC	United States	$9.60M	2,227,516	45.78%	54.22%	Net Buying
SLRX	SALARIUS PHARMACEUTICALS INC	United States	$2.15M	4,314,433	2.20%	97.80%
LENZ	LENZ THERAPEUTICS INC	United States	$128.54M	8,319,561	49.99%	50.01%	Net Buying	Net Buying
BLTE	BELITE BIO INC	United States	$1.11B	29,149,444	0.53%	0.00%
BMEA	BIOMEA FUSION INC	United States	$375.76M	35,889,360	61.83%	38.17%	Net Selling
INSM	INSMED INC	United States	$3.70B	148,491,583	79.99%	20.01%	Net Buying	Net Buying
RLYB	RALLYBIO CORP	United States	$62.39M	37,811,970	43.27%	56.73%
TARA	PROTARA THERAPEUTICS INC	United States	$34.87M	11,433,837	11.95%	88.05%	Net Selling
SYRE	SPYRE THERAPEUTICS INC	United States	$1.17B	36,150,941	52.09%	47.91%	Net Buying	Net Buying
EDSA	EDESA BIOTECH INC	Canada	$14.17M	3,171,760	1.29%	98.71%	Net Buying	Net Buying
HLVX	HILLEVAX INC	United States	$597.40M	49,700,828	65.85%	34.15%	Net Selling	Net Selling
RARE	ULTRAGENYX PHARMACEUTICAL INC	United States	$3.61B	82,335,687	83.47%	16.53%	Net Selling	Net Selling
GHRS	GH RESEARCH PLC	Ireland	$546.30M	52,028,145	56.89%	0.00%
PDSB	PDS BIOTECHNOLOGY CORP	United States	$119.57M	36,679,275	22.71%	31.97%
IMMX	IMMIX BIOPHARMA INC	United States	$55.43M	26,396,420	2.96%	31.19%	Net Buying
CRIS	CURIS INC	United States	$85.58M	5,894,085	3.46%	96.54%
CMND	CLEARMIND MEDICINE INC	Canada (Federal Level)	$3.80M	3,169,570	2.92%	0.00%
OPT	OPTHEA LTD	Australia	$211.97M	467,159,374	1.53%	0.00%
GNTA	GENENTA SCIENCE SPA	Italy	$53.08M	18,216,958	2.53%	0.00%
TPST	TEMPEST THERAPEUTICS INC	United States	$77.23M	22,192,026	4.15%	95.85%
AIM	AIM IMMUNOTECH INC	United States	$20.26M	49,901,177	8.32%	9.92%	Net Buying	Net Buying

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -30.41% over the past year, underperforming other biotech stocks by -7 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 45.94% from Incyte's current stock price of $51.18.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -8.91% over the past year, overperforming other biotech stocks by 15 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 29.05% from Harmony Biosciences Holdings's current stock price of $28.93.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -1.33% over the past year, overperforming other biotech stocks by 22 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 176.28% from Voyager Therapeutics's current stock price of $7.42.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 14.87%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)

Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 56.45%, which is 42 percentage points higher than the biotech industry average of 14.87%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)

Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.09%, which is -14 percentage points lower than the biotech industry average of 14.87%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.43% in the last day, and down -0.98% over the last week. Acrivon Therapeutics was the among the top losers in the biotechnology industry, dropping -10.84% yesterday.

Acrivon Therapeutics shares are trading higher after the company reported initial clinical data for ACR-368 and pipeline program progress today at a corporate R&D event.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -21.04% in the past year. It has overperformed other stocks in the biotech industry by 3 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -1.33% in the past year. It has overperformed other stocks in the biotech industry by 22 percentage points.

3. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -30.41% in the past year. It has underperformed other stocks in the biotech industry by -7 percentage points.

Are biotech stocks a good buy now?

49.03% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 94.43% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.41x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.